Abstract FLASH radiotherapy (FLASH-RT) is a promising research direction in medical physics and cancer treatment. It involves delivering radiation at ultra-high dose rates over very short periods. Preclinical studies have demonstrated reduced injury to certain normal tissues while maintaining tumour response under specific experimental conditions. This article examines the physical principles of FLASH-RT, proposed biological mechanisms, challenges in beam generation and dosimetry, and its therapeutic potential, while outlining the limitations of the available clinical evidence. Keywords: FLASH radiotherapy, ultra-high dose rates, medical physics, dosimetry, oxygen, normal tissue sparing. Introduction Radiotherapy aims to deliver a sufficient dose to control a tumour while limiting damage to healthy tissues. Conventional advances have focused on dose distribution and beam targeting, whereas FLASH radiotherapy introduces another dimension: the time over which the dose is delivered. FLASH research commonly uses average dose rates of 40 Gy/s or higher, with the prescribed dose for an irradiation exposure delivered within a fraction of a second in many experimental applications. However, exceeding this rate alone does not guarantee the desired biological effect. Total dose, pulse structure, irradiated volume, and oxygenation also influence the response. A short irradiation time does not necessarily mean that an entire treatment course is delivered in one session. It also does not eliminate the time required for imaging, patient positioning, and treatment verification. 1. The FLASH Effect The FLASH effect refers to reduced normal tissue injury following ultra-high-dose-rate irradiation compared with conventional irradiation at a comparable dose, while maintaining antitumour activity in several experimental models. A landmark preclinical study demonstrated protection of mouse lung tissue while preserving tumour growth suppression. These findings do not establish protection across all organs, tumours, or irradiation conditions. Producing an ultra-high-dose-rate beam must therefore be distinguished from demonstrating the biological FLASH effect. 2. Physical Principles Dose Rate and Temporal Beam Structure The average dose rate is expressed as: [ \dot{D}_{\mathrm{avg}}=\frac{D}{\Delta t} ] Here, (D) is the absorbed dose in gray, and (\Delta t) is the delivery time in seconds. For example, delivering 8 Gy over 0.1 seconds gives an average dose rate of: [ \dot{D}_{\mathrm{avg}}=\frac{8}{0.1}=80\ \mathrm{Gy/s} ] This calculation illustrates dose rate; it does not independently demonstrate a FLASH effect. For pulsed beams, the average dose rate must be distinguished from the dose rate within each pulse, which can be considerably higher. Other important parameters include dose per pulse, pulse duration, repetition frequency, and intervals between pulses. Radiation Sources FLASH techniques are being investigated using electrons, protons, and photons, alongside research involving other particles. Engineering requirements vary with beam type, energy, and irradiation volume. Low- and medium-energy electrons have limited penetration for deep-seated tumours. Very-high-energy electrons are being investigated to extend their treatment depth. Protons and photons offer possibilities for deeper targets, although achieving ultra-high dose rates with suitable dose distributions remains technically challenging. 3. Proposed Biological and Chemical Mechanisms Oxygen Depletion Hypothesis This hypothesis proposes that chemical reactions triggered by rapid irradiation consume some local oxygen before it can be replenished, potentially reducing the fixation of oxygen-dependent radiation damage. Experimental measurements do not support an assumption of severe, widespread oxygen depletion in all healthy tissues. A direct measurement study indicated that the observed oxygen consumption might be insufficient to produce radiobiologically significant hypoxia throughout bulk tissue. Oxygen depletion therefore remains a possible contributing mechanism rather than an established explanation. Free Radicals and Radiation Chemistry Radiation causes water radiolysis, generating reactive chemical species capable of damaging cellular components. Closely spaced radiation events may alter radical interactions and recombination, affecting the quantity and lifetime of damaging products. Research models suggest that radical reactions and differences in cellular responses to oxidative stress may contribute to tissue sparing. The relative contribution of each pathway remains uncertain. Cellular and Tissue Responses Processes under investigation include DNA damage and repair, inflammatory responses, and vascular and immune changes. It cannot be assumed that FLASH consistently causes less DNA damage in normal cells or prevents cell death. Findings depend on cell type, tissue, dose, and experimental conditions. 4. Technical and Dosimetric Challenges Beam generation and stability: Delivering a substantial dose within an extremely short interval requires precise control of beam intensity, energy, and uniformity. Not all conventional treatment systems can achieve FLASH conditions without modifications or specialised equipment. Dosimetry: Conventional ionisation chambers may experience increased ion recombination at high doses per pulse, reducing their response or introducing nonlinearity. Complementary approaches include radiochromic films, scintillation and diamond detectors, and calorimetry, with calibration appropriate to the beam conditions. Treatment planning: Planning must account for both spatial and temporal dose distributions. Different parts of a target may experience different dose rates, particularly when a beam is scanned across a large volume. Quality assurance and safety: Very short irradiation times increase the importance of pretreatment dose verification, accurate patient positioning, rapid beam monitoring, and reliable safety interlocks. Early clinical studies have highlighted these requirements. 5. Therapeutic Potential and Clinical Evidence The intended benefit is an improved therapeutic ratio: effective tumour control with less normal tissue injury. If confirmed clinically, this could support reductions in selected complications or carefully investigated dose escalation in suitable patients. Short irradiation times may also reduce the influence of some patient movements during beam delivery. However, the complete treatment appointment still requires preparation and verification. In the FAST-01 trial, ten patients with painful bone metastases in the extremities received ultra-high-dose-rate proton treatment. The findings supported clinical feasibility and demonstrated pain relief with limited adverse effects consistent with the treatment delivered. However, this small, nonrandomised study did not establish superior normal tissue protection or long-term tumour control compared with conventional radiotherapy. Comparative studies with adequate follow-up remain necessary to establish therapeutic benefit, identify suitable patients and tumour sites, and define effective dose and temporal delivery conditions. Conclusions FLASH radiotherapy brings together accelerator physics, radiation chemistry, and radiobiology. Preclinical findings support the possibility of reducing injury to certain normal tissues while preserving antitumour activity under defined conditions. Early human studies provide evidence of clinical feasibility. Nevertheless, universal tissue protection, improved cure rates, and reduced complications have not yet been established. Progress depends on understanding the underlying mechanisms, strengthening dosimetry and quality assurance, and conducting clinical studies that can determine the technique’s benefits and limitations. Almustaqbal University – The First University in Iraq